Foresite Capital Management V, LLC
Position in LYEL — Lyell Immunopharma, Inc.
CIK 1792206
WEST HOLLYWOOD, CA
Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$9,570,184
-$5,114,276 QoQ
Shares Held
477,078
0.0% QoQ
Ownership
2.04%
of shares outstanding
% of Portfolio
3.53%
of 13F equity value
Holder Rank
#7
of 72 holders
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Foresite Capital Management V, LLC holds $255,672,693 across 8 Biotechnology names. LYEL ranks #5 (3.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALMS |
Alumis Inc.
|
5,896,995 | $129,910,799 | |
| 2 | CGON |
CG Oncology, Inc.
|
1,004,050 | $67,954,104 | |
| 3 | IRON |
Disc Medicine, Inc.
|
374,069 | $23,917,971 | |
| 4 | EIKN |
Eikon Therapeutics, Inc.
|
1,318,983 | $13,954,840 | |
| 5 | LYEL |
Lyell Immunopharma, Inc.
This page
|
477,078 | $9,570,184 | |
| 6 | PHVS |
Pharvaris N.V.
|
194,125 | $5,484,031 | |
| 7 | NRIX |
Nurix Therapeutics, Inc.
|
265,000 | $4,107,500 | |
| 8 | MAZE |
Maze Therapeutics, Inc.
|
25,905 | $773,264 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,570,184 | 477,078 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $14,684,460 | 477,078 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $7,747,746 | 477,078 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $3,594,803 | 406,652 | Shares | Sole | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||